Laryngeal cancer secondary prevention: Difference between revisions
Jump to navigation
Jump to search
(Mahshid) |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}}{{Faizan}} | {{CMG}} {{AE}}{{Faizan}} | ||
==Overview== | ==Overview== | ||
Secondary prevention measures of laryngeal cancer include routine physical examination and imaging at scheduled intervals after treatment. Dental screening and screening for thyroid cancers are recommended among patients who had received radiation therapy to the oral cavity and cervical region, respectively | [[Secondary prevention]] measures of [[laryngeal cancer]] include routine [[physical examination]] and [[imaging]] at scheduled intervals after treatment. [[Dental]] [[screening]] and [[screening]] for [[thyroid cancers]] are recommended among [[patients]] who had received [[radiation therapy]] to the [[oral cavity]] and [[cervical]] region, respectively | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
===Follow up after treatment=== | ===Follow up after treatment=== | ||
Patients treated for laryngeal carcinoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:<ref name="pmid23946171">{{cite journal| author=Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ et al.| title=Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 8 | pages= 917-23 | pmid=23946171 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23946171 }} </ref> | Patients treated for [[laryngeal carcinoma]] should follow-up for [[secondary prevention]]. Follow-up measures are shown in the table below:<ref name="pmid23946171">{{cite journal| author=Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ et al.| title=Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 8 | pages= 917-23 | pmid=23946171 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23946171 }} </ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align="center" | ||
|valign=top| | | valign="top" | | ||
|+ | |+ | ||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Follow up}} | ! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Follow up}} | ||
| Line 26: | Line 26: | ||
:Nasendoscopy | :Nasendoscopy | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Immediately following radiation therapy | *Immediately following [[radiation therapy]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
:CT Scan/MRI | :CT Scan/MRI | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Imaging studies are performed at routine intervals as follows: | *[[Imaging]] studies are performed at routine intervals as follows: | ||
:*Baseline scanning is performed at 3-6 months after treatment, further scans are scheduled based on finding of physical exam and symptoms experienced by the patient | :*Baseline scanning is performed at 3-6 months after treatment, further scans are scheduled based on finding of [[physical exam]] and [[Symptom|symptoms]] experienced by the patient | ||
:*Scanning for asymptomatic patients is not recommended | :*Scanning for asymptomatic [[patients]] is not recommended | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
:Thyroid hormone testing | :Thyroid hormone testing | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Thyroid stimulating hormone testing every 12 months if the neck was exposed to radiation | *[[Thyroid-stimulating hormone|Thyroid stimulating hormone]] testing every 12 months if the [[neck]] was exposed to [[radiation]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | ||
:Dental screening | :Dental screening | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
*Only recommended if oral cavity was exposed to radiation | *Only recommended if [[oral cavity]] was exposed to [[radiation]] | ||
|- | |- | ||
|} | |} | ||
Revision as of 03:08, 11 January 2019
|
Laryngeal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Laryngeal cancer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Laryngeal cancer secondary prevention |
|
Risk calculators and risk factors for Laryngeal cancer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
Secondary prevention measures of laryngeal cancer include routine physical examination and imaging at scheduled intervals after treatment. Dental screening and screening for thyroid cancers are recommended among patients who had received radiation therapy to the oral cavity and cervical region, respectively
Secondary Prevention
Follow up after treatment
Patients treated for laryngeal carcinoma should follow-up for secondary prevention. Follow-up measures are shown in the table below:[1]
| Follow up | Description |
|---|---|
|
|
|
|
|
|
|
|
|
|
References
- ↑ Pfister DG, Ang KK, Brizel DM, Burtness BA, Busse PM, Caudell JJ; et al. (2013). "Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (8): 917–23. PMID 23946171.